







T cells develop and differentiate in the 
thymus. Cytokines and signals from antigen 
presenting cells cause thymocytes to 
differentiate into various functional classes, 
each with a unique gene expression pattern. 
Naive helper (CD4+) and cytotoxic (CD8+) T 
cells further differentiate into central 
memory, effector memory, or terminally 
differentiated T cells. Central memory cells 
survive and proliferate for an extended
period, allowing for subsequent immune 
responses. Effector memory cells release 
cytokines and die within a few days. 
Terminally differentiated cells have 
immediate inflammatory effects and low 
proliferative capacity. 
Chimeric antigen receptor modified T cells 
(CAR-T cells) are effective antitumor agents 
when treating chronic lymphocytic leukemia 
and acute lymphoblastic leukemia. However, 
attempts to treat other types of leukemia, as 
well as solid tumors, with CAR-T cells have 
been less successful. One of the major 
barriers to widespread use of CAR-T cells is 
their toxicity. 
CAR-T cells cause cytokine release 
syndrome (CRS), on-target off-tumor effects, 
and neurological toxicities. CRS occurs due 
to buildup of cytokines following the
activation of immune cells, which leads to 
inflammation and disrupts the normal 
function of cells. CAR-T cells cause on-
target off-tumor effects when they target 
antigens which present on both healthy and 
tumor cells. Several deaths in clinical trials 
have been attributed to these.
The addition of a “suicide gene” encoding 
the caspase-9 protein to CAR-T cells has 
been proposed as a method to decrease 
their toxicity. This strategy uses rimiducid 
(AP1903), a drug that causes dimerization of 
the caspase-9 protein. Dimerization of 
caspase-9 domains leads to CAR-T cell 
death and thereby prevents inflammation 
and off-tumor effects.
Early trials have found that the “suicide 
gene” and rimiducid are able to decrease the 
toxicity of CAR-T cells. However, the effect
of this drug on the native population of T
cells is unknown.
Methods
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat by layering with 
Ficoll-HISTOPAQUE-1077 and centrifugation. PBMCs were divided into three time points (days four, six, 
and seven) and three treatments. The control group was not treated. The stimulation group was treated 
with CD3 and CD28. The rimiducid group was treated with CD3 and CD28 as well as 2μL of 1mM 
rimiducid. Cells were mixed with antibodies for various markers of T cell development and differentiation 
and were analyzed using flow cytometry.
Conclusions
Treatment with rimiducid increases the prevalence 
of helper T cells (CD4) in vitro. It also increases 
the prevalence of naive helper T cells while 
decreasing the prevalence of central memory and 
terminally differentiated helper T cells.
Rimiducid does not appear to affect the prevalence 
of cytotoxic (CD8) T cells or the differentiation of 
these cells in vitro. 
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Figure 2: Development of helper T cells. A. Flow cytometry data showing fluorescence of helper T cells for 
markers of CD45RA and CD27. B. Average percentage of cell types on day four. Error bars represent one standard 
deviation. C. Average percentage of cell types on day six. Error bars represent one standard deviation. Rimiducid 
increases the abundance of naive helper T cells (p<.001) while decreasing the percentage of central memory 
(p=.00296) and terminally differentiated (p=.0455) T cells.
Objective
To determine if rimiducid influences the 
development and differentiation of human T 
cells. If this drug is to be used clinically, it is 
important to understand any effects it may 






Figure 3:  Development of cytotoxic T cells. A. Flow 
cytometry data showing fluorescence of cytotoxic T 
cells for markers of CD45RA and CD27. B. Average 
percentage of cell types on day seven. Error bars 
represent one standard deviation. Rimiducid does not 
appear to affect the development of CD8 T cells.












































Figure 1: Differentiation of thymocytes into helper and cytotoxic T cells. A. Flow cytometry data showing 
fluorescence of single T cells for markers of CD4 and CD8. B. Average percentage of CD4+ cells. Error bars
represent one standard deviation. C. Average percentage of CD8+ cells. Error bars represent one standard 
deviation. Rimiducid appears to increase the percentage of helper T cells (p=.0159) and not have an affect on the 












































































































































Rimiducid Stimulates Differentiation of Thymocytes into Helper T Cells 
and Inhibits Development of Central Memory Helper T Cells
Brian Dineen1,2, Dan Li1, Rolando Vedia1, Mao Zhang1, Qing Ma1
University of Texas MD Anderson Cancer Center Department of Hematopoietic Biology and Malignancy1 
University of Notre Dame2
Results (continued)
